Globitair

Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

Financial PostUnited States of America

ORZEYFULTM approved in the U.S., Japan and China for narcolepsy type 1 (NT1), MIMRYLOTM launched in the U.S. for erythrocytosis in polycythemia vera (PV) Zasocitinib advances to U.S. Food & Drug Administration (FDA) Priority Review and European Medicines Agency (EMA) review Late-stage pipeline continues to advance FY2026 full-year outlook upgraded to reflect foreign exchange (FX) […]

Read the full story at Financial PostOpen in the live monitor

Related discussion groups

No group discusses this yet. Start a discussion group and attach this story.

More news about United States of America